The global glaucoma therapeutics market size is expected to Reach US$ 7,600 Mn by 2026 and is projected to expand at a CAGR of 3.2% from 2019 to 2026. Increase in prevalence and incidence of diabetic disorders, rise in geriatric population, improved health care as well as health care infrastructure, and introduction of combination therapies are anticipated to propel the global market from 2019 to 2026.
The report analyzes and forecasts the glaucoma therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of glaucoma therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major glaucoma therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of glaucoma therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of glaucoma therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global glaucoma therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the glaucoma therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of glaucoma therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive Landscape
The report also profiles major players in the global glaucoma therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals International, Inc., and Aerie Pharmaceuticals, Inc.
The global glaucoma therapeutics Market has been segmented as follows:
Global Glaucoma Therapeutics Market, by Drug Class
Global Glaucoma therapeutics Market, by End-user
Global Glaucoma therapeutics Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2019–2026
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Value Chain Analysis
5.2. Disease Prevalence & Incidence Rate, by Region
5.3. Healthcare Industry Overview
5.4. Pipeline Analysis
6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2019–2026
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Carbonic Anhydrase Inhibitors
6.3.5. Combination Medications
6.3.6. Cholinergics
6.4. Market Attractiveness, by Drug Class
7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2019–2026
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user
8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Drug Class, 2019–2026
9.2.1. Prostaglandins
9.2.2. Beta Blockers
9.2.3. Alpha Agonists
9.2.4. Carbonic Anhydrase Inhibitors
9.2.5. Combination Medications
9.2.6. Cholinergics
9.3. Market Value Forecast, by End-user, 2019–2026
9.3.1. Hospitals
9.3.2. Ophthalmic Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2019–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By End-user
9.5.3. By Country
10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2019–2026
10.2.1. Prostaglandins
10.2.2. Beta Blockers
10.2.3. Alpha Agonists
10.2.4. Carbonic Anhydrase Inhibitors
10.2.5. Combination Medications
10.2.6. Cholinergics
10.3. Market Value Forecast, by End-user, 2019–2026
10.3.1. Hospitals
10.3.2. Ophthalmic Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2019–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2019–2026
11.2.1. Prostaglandins
11.2.2. Beta Blockers
11.2.3. Alpha Agonists
11.2.4. Carbonic Anhydrase Inhibitors
11.2.5. Combination Medications
11.2.6. Cholinergics
11.3. Market Value Forecast, by End-user, 2019–2026
11.3.1. Hospitals
11.3.2. Ophthalmic Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2019–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2019–2026
12.2.1. Prostaglandins
12.2.2. Beta Blockers
12.2.3. Alpha Agonists
12.2.4. Carbonic Anhydrase Inhibitors
12.2.5. Combination Medications
12.2.6. Cholinergics
12.3. Market Value Forecast, by End-user, 2019–2026
12.3.1. Hospitals
12.3.2. Ophthalmic Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2019–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2019–2026
13.2.1. Prostaglandins
13.2.2. Beta Blockers
13.2.3. Alpha Agonists
13.2.4. Carbonic Anhydrase Inhibitors
13.2.5. Combination Medications
13.2.6. Cholinergics
13.3. Market Value Forecast, by End-user, 2019–2026
13.3.1. Hospitals
13.3.2. Ophthalmic Clinics
13.3.3. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2019–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company (2019)
14.3. Company Profiles
14.3.1. Allergan plc
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Novartis AG
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Santen Pharmaceuticals Co. Ltd.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. Valeant Pharmaceuticals International, Inc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Aerie Pharmaceuticals Inc.
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.7.4 Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers